Related posters
(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model
CTLA-4 & survival in a colorectal cancer model
April 14, 2023
Abstract
Systemic therapy with CTLA-4 blocking antibody (aCTLA4) restores endogenous anti tumor immunity and induces remarkable long-term clinical benefits in patients with melanoma. Yet immune-related side effects remain a major hurdle to extend its label to many more types of cancer. Intra- and peritumoral administration of aCTLA4 has recently emerged to optimize its dose/efficacy ratio while preventing its on-target, off-tumor systemic toxicities. Sustained delivery of low dose aCTLA4 by genetically engineered encapsulated cells (MVX-3) could offer a promising option for cancer treatment addressing the shortcomings of systemic therapy.
Scientific excellence
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Robust validation data on catalog models
Comprehensive dataset package
Generated with biopharma partners and in-house
Customer care
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Easy and fast access to models
Breeding facilities in US and Europe
Certified health status from professional breeders